조진균증 시장 - 예측(2026-2031년)

Onychomycosis Market is anticipated to increase at a 4.42% CAGR, growing from USD 4.733 billion in 2025 to USD 6.136 billion in 2031.

The onychomycosis market is experiencing rapid growth driven by increasing prevalence of this contagious disease affecting finger and toe nails, along with rising demand for advanced diagnostic and treatment solutions. The market deals with diagnosis, treatment, and management of fungal infections affecting nails, with several companies investing in development of new treatments and therapies. The market is expected to hold significant value in coming years as increasing awareness about the condition and availability of advanced diagnostic and treatment options drive expansion.

Market Definition and Clinical Framework

Onychomycosis represents a fungal infection that influences the nails of fingers and toes. The onychomycosis treatment market is growing rapidly due to rising prevalence and development of advanced diagnostic and treatment methods. The market can be segmented by type, diagnosis, and treatment, providing comprehensive approaches to managing this condition across diverse patient populations.

Companies are developing innovative antifungal therapies to improve treatment efficacy and patient outcomes. However, stringent regulatory requirements for approval of new drugs and therapies may negatively impact market growth by extending development timelines and increasing costs associated with bringing new treatments to market. Despite these regulatory challenges, the overall market trajectory remains positive as unmet medical needs continue driving innovation and investment.

Market Growth Catalysts

Increasing prevalence represents one of the essential drivers of the market. The rising pervasiveness of onychomycosis is driving demand for cutting-edge analytics and treatment choices. The condition is normal in both created and non-industrial nations, with rising occurrence of the disease driving interest in advanced diagnostic and treatment options across diverse geographic regions and patient demographics.

Technological advancements are propelling market development significantly. The improvement of cutting-edge demonstrative and treatment choices is driving onychomycosis market growth. The accessibility of innovations, such as laser treatment and photodynamic treatment, is working on the adequacy of treatment and diminishing time expected for treatment. These advanced therapeutic modalities provide alternatives to traditional antifungal medications, offering improved outcomes for patients who may not respond adequately to conventional treatments.

Awareness and education initiatives are expanding market opportunities. The rising mindfulness about onychomycosis and its side effects are driving interest in demonstrative and treatment choices. The accessibility of instructive assets and mindfulness crusades is assisting with expanding mindfulness about the condition and diminishing disgrace related to it. As patients become more informed about fungal nail infections and available treatment options, they are more likely to seek medical care, driving market growth through increased diagnosis and treatment rates.

Aging population dynamics are contributing substantially to market expansion. The maturing populace is more defenseless to onychomycosis, with rising numbers of old individuals driving market development. The predominance of onychomycosis in old individuals is confounded by illnesses, for example, diabetes and fringe vascular sickness, which increment the gamble of contamination. The North American market is expanding due to rising geriatric population and higher infection awareness, positioning this demographic as a key growth driver.

Psychosocial and emotional effects represent important market drivers. The psychosocial and profound impacts coming about because of onychomycosis are far-reaching and may fundamentally affect personal satisfaction. The effect of the condition on personal satisfaction is driving interest in compelling treatment choices that can further develop physical and close-to-home prosperity of patients. Recognition that onychomycosis extends beyond purely physical symptoms to affect psychological wellbeing and social functioning is motivating both patients and healthcare providers to pursue more effective treatments.

Treatment Innovation and Development

Major pharmaceutical companies are advancing therapeutic options through innovative approaches. Almirall offers treatments including terbinafine nail solutions that have proven effective in clinical trials and are expected to be key products in coming years. Onycho Pharma is developing AMYCOT, a profoundly effectual normally inferred item to treat onychomycosis utilizing licensed bioactive concentrate detailing to outfit counter parasitic properties from cyanobacteria strain Arthrospira Maxima.

Hexima is developing a new class of antifungal peptides with broad-spectrum activity against fungal species. The peptides are designed to be safe and effective and have potential to represent significant advances in onychomycosis treatment. These innovative therapeutic approaches demonstrate industry commitment to addressing unmet medical needs through novel mechanisms of action and improved therapeutic profiles.

Segment Analysis

The white superficial onychomycosis segment is witnessing rapid growth from improved detection and targeted therapies. White superficial onychomycosis is a subtype characterized by white chalky deposits on the surface of affected nail plates. This subtype is caused by direct invasion of nail plate surface by fungus and can be easily scraped away with curette or rotary burr.

The white superficial onychomycosis segment is experiencing rapid growth due to increasing incidence of immunocompromised conditions and rising awareness and diagnosis of fungal nail infections. The most common clinical subtype of onychomycosis is distal lateral subungual onychomycosis, which presents as partial distal onycholysis with subungual hyperkeratosis or crumbling.

Regional Market Leadership

The North American region is expected to hold significant market share due to high drug costs, rising geriatric population, and increasing incidence of fungal nail infections. The region has seen growing awareness of vast potential of onychomycosis drugs, fueling market expansion. Rising awareness and diagnosis of fungal nail infections in North America are contributing to market growth, positioning the region as a key geographic market for onychomycosis treatments and diagnostics.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2021 to 2025 & forecast data from 2026 to 2031
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information), and Key Developments among others.

Onychomycosis Market Segmentation

• By Type
• Distal Subungual Onychomycosis
• White Superficial Onychomycosis
• Proximal Subungual Onychomycosis
• Others
• By Treatment Type
• Oral
• Topical
• Others
• By Distribution Channel
• Institutional Sales
• Retail Sales
• By Geography
• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• Japan
• India
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. ONYCHOMYCOSIS MARKET BY TYPE

• 5.1. Introduction
• 5.2. Distal Subungual Onychomycosis
• 5.3. White Superficial Onychomycosis
• 5.4. Proximal Subungual Onychomycosis
• 5.5. Others

6. ONYCHOMYCOSIS MARKET BY TREATMENT TYPE

• 6.1. Introduction
• 6.2. Oral
• 6.3. Topical
• 6.4. Others

7. ONYCHOMYCOSIS MARKET BY DISTRIBUTION CHANNEL

• 7.1. Introduction
• 7.2. Institutional Sales
• 7.3. Retail Sales

8. ONYCHOMYCOSIS MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. USA
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. United Kingdom
  • 8.4.2. Germany
  • 8.4.3. France
  • 8.4.4. Spain
  • 8.4.5. Others
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Others
• 8.6. Asia Pacific
  • 8.6.1. China
  • 8.6.2. Japan
  • 8.6.3. India
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Thailand
  • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Almirall
• 10.2. Onycho Pharma
• 10.3. Blue Cross NC
• 10.4. Hexima
• 10.5. Hallux Inc
• 10.6. Bausch Health
• 10.7. Canesten UK
• 10.8. Julbliarx
• 10.9. Ferozsons Laboratories Limited
• 10.10. Pfizer
• 10.11. Galderma

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key Benefits for the Stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations